HRDVinactive

HEALTH-RIGHT DISCOVERIES, INC.

·Commercial

ImmunologyOphthalmologyInfectious DiseasePainMusculoskeletalGastroenterology

What we can confirm

BioSniper Score:: 2.7 / 10
Lead Asset:: h-plex defense (Preclinical)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 2.7 / 10 · Lead Asset: h-plex defense (Preclinical)

BioSniper AIPage evidence connected

Prepared research question

What matters most for HRDV—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

2.7/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

h-plex defense (Preclinical)

Next Catalyst

—

Tracking 1 pipeline candidate for HEALTH-RIGHT DISCOVERIES, INC..

Run HEALTH-RIGHT DISCOVERIES, INC. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

Turn available HEALTH-RIGHT DISCOVERIES, INC. facts into screen rules or deeper checks
Show cited findings, blockers, and unresolved evidence together
Save the logic and rerun it as the company evidence changes

Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Frequently asked questions

What is HEALTH-RIGHT DISCOVERIES, INC.'s lead drug candidate?

HEALTH-RIGHT DISCOVERIES, INC.'s most advanced tracked candidate is h-plex defense (Preclinical) for Herpes Simplex Virus 1 (HSV-1).

What therapeutic areas does HEALTH-RIGHT DISCOVERIES, INC. focus on?

HEALTH-RIGHT DISCOVERIES, INC. develops therapies across Immunology, Ophthalmology, Infectious Disease, Pain, Musculoskeletal, Gastroenterology.

923 companies304,844 SEC filings22,644 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.